Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RCT1100 in Healthy Adults and Adults With Primary Ciliary Dyskinesia
NCT05737485Phase 1Completed
- Sponsor
- ReCode Therapeutics
- Start
- Feb 2023
- Primary completion
- Jul 2024
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in primary ciliary dyskinesia (PCD) comparing RCT1100 with Placebo (2 arms). Primary endpoint: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 180. Started Feb 2023; status: completed.
02
Drugs
RCT1100
03
Conditions
primary ciliary dyskinesia (PCD)
Beyond the preview
Go deeper on NCT05737485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05737485.